Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study.
AuthorsCoutinho, Lucia H
Brereton, M L
Morgenstern, Godfrey R
Scarffe, J Howard
Harrison, Christine J
Yin, J A
Darbyshire, P J
Dexter, T Michael
Testa, Nydia G
AffiliationCRC Department of Experimental Haematology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractIncubation of CML marrow in long-term culture (LTC) conditions may result in selection of normal (Ph-) LTC-initiating cells (LTC-IC) as early as 10 days, and in production of Ph- clonogenic cells and mature end cells within 5 weeks. This was the rationale for using marrow cells from 10-day-old LTC to autograft nine chronic phase CML patients, ineligible for HLA-matched sibling donor transplant, and who were selected on the basis of a pre-transplant screening LTC test. Of the transplanted patients three died; two of graft failure and one of therapy-related toxicity with 97% Ph- cells 16 months following the autograft. The reconstituting haemopoietic cells in the seven engrafted patients were 100% Ph- in four, > or = 90% Ph- in two and 71% Ph- in the seventh, with a duration of complete cytogenetic response of 6-12 months. Three patients reverted to chronic phase and 100% Ph+ haemopoiesis 27-36 months post-autograft. The other three patients remain in continuous haematological remission with 22% Ph- cells in one and complete cytogenetic remission in the other two 3-4 years post-autograft. IFN therapy was generally introduced on the first evidence of recurrence of Ph+ cells or of cytogenetic deterioration. Further strategies to modulate immune surveillance in vivo may improve the outcome of cultured marrow autografts which give an initial and rather prolonged bias towards Ph- haemopoiesis.
CitationAutografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study. 1997, 19 (10):969-76 Bone Marrow Transplant.
JournalBone Marrow Transplantation
- Autografting in chronic myeloid leukemia with cultured marrow: update of the Vancouver Study.
- Authors: Barnett MJ, Eaves CJ, Phillips GL, Hogge DE, Klingemann HG, Lansdorp PM, Nantel SH, Reece DE, Shepherd JD, Sutherland HJ
- Issue date: 1993 Oct
- Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
- Authors: Carlo-Stella C, Regazzi E, Andrizzi C, Savoldo B, Garau D, Montefusco E, Vignetti M, Mandelli F, Rizzoli V, Meloni G
- Issue date: 1997 May-Jun
- Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study.
- Authors: Barnett MJ, Eaves CJ, Phillips GL, Gascoyne RD, Hogge DE, Horsman DE, Humphries RK, Klingemann HG, Lansdorp PM, Nantel SH
- Issue date: 1994 Aug 1
- Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis.
- Authors: Podestà M, Piaggio G, Sessarego M, Pitto A, Figari O, Soracco M, Carella AM, Dejana A, Rosti V, Fugazza G, Ravera G, Lerma E, Cazzola M, Bacigalupo A, Frassoni F
- Issue date: 2000 Feb
- BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
- Authors: de Fabritiis P, Petti MC, Montefusco E, De Propris MS, Sala R, Bellucci R, Mancini M, Lisci A, Bonetto F, Geiser T, Calabretta B, Mandelli F
- Issue date: 1998 May 1